2vu9 Citations

Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction.

OpenAccess logo PLoS Pathog 4 e1000129 (2008)
Cited: 105 times
EuropePMC logo PMID: 18704164

Abstract

Botulinum neurotoxins have a very high affinity and specificity for their target cells requiring two different co-receptors located on the neuronal cell surface. Different toxin serotypes have different protein receptors; yet, most share a common ganglioside co-receptor, GT1b. We determined the crystal structure of the botulinum neurotoxin serotype A binding domain (residues 873-1297) alone and in complex with a GT1b analog at 1.7 A and 1.6 A, respectively. The ganglioside GT1b forms several key hydrogen bonds to conserved residues and binds in a shallow groove lined by Tryptophan 1266. GT1b binding does not induce any large structural changes in the toxin; therefore, it is unlikely that allosteric effects play a major role in the dual receptor recognition. Together with the previously published structures of botulinum neurotoxin serotype B in complex with its protein co-receptor, we can now generate a detailed model of botulinum neurotoxin's interaction with the neuronal cell surface. The two branches of the GT1b polysaccharide, together with the protein receptor site, impose strict geometric constraints on the mode of interaction with the membrane surface and strongly support a model where one end of the 100 A long translocation domain helix bundle swing into contact with the membrane, initiating the membrane anchoring event.

Reviews - 2vu9 mentioned but not cited (4)

  1. Botulinum and Tetanus Neurotoxins. Dong M, Masuyer G, Stenmark P. Annu Rev Biochem 88 811-837 (2019)
  2. Assembly and function of the botulinum neurotoxin progenitor complex. Gu S, Jin R. Curr Top Microbiol Immunol 364 21-44 (2013)
  3. Variations in the Botulinum Neurotoxin Binding Domain and the Potential for Novel Therapeutics. Davies JR, Liu SM, Acharya KR. Toxins (Basel) 10 E421 (2018)
  4. A Comprehensive Structural Analysis of Clostridium botulinum Neurotoxin A Cell-Binding Domain from Different Subtypes. Gregory KS, Acharya KR. Toxins (Basel) 15 92 (2023)

Articles - 2vu9 mentioned but not cited (19)



Reviews citing this publication (22)

  1. Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration. Schnaar RL, Gerardy-Schahn R, Hildebrandt H. Physiol Rev 94 461-518 (2014)
  2. Botulinum neurotoxin: a marvel of protein design. Montal M. Annu Rev Biochem 79 591-617 (2010)
  3. Cell entry strategy of clostridial neurotoxins. Binz T, Rummel A. J Neurochem 109 1584-1595 (2009)
  4. Clostridial toxins. Popoff MR, Bouvet P. Future Microbiol 4 1021-1064 (2009)
  5. Bacterial Signaling to the Nervous System through Toxins and Metabolites. Yang NJ, Chiu IM. J Mol Biol 429 587-605 (2017)
  6. The Polyomaviridae: Contributions of virus structure to our understanding of virus receptors and infectious entry. Neu U, Stehle T, Atwood WJ. Virology 384 389-399 (2009)
  7. Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review. Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF. Headache 60 1259-1272 (2020)
  8. Receptor and substrate interactions of clostridial neurotoxins. Brunger AT, Rummel A. Toxicon 54 550-560 (2009)
  9. Therapeutic use of botulinum toxin in migraine: mechanisms of action. Ramachandran R, Yaksh TL. Br J Pharmacol 171 4177-4192 (2014)
  10. Bacterial toxins and the nervous system: neurotoxins and multipotential toxins interacting with neuronal cells. Popoff MR, Poulain B. Toxins (Basel) 2 683-737 (2010)
  11. Molecular recognition of gangliosides and their potential for cancer immunotherapies. Krengel U, Bousquet PA. Front Immunol 5 325 (2014)
  12. Engineered botulinum neurotoxins as new therapeutics. Masuyer G, Chaddock JA, Foster KA, Acharya KR. Annu Rev Pharmacol Toxicol 54 27-51 (2014)
  13. Molecular structures and functional relationships in clostridial neurotoxins. Swaminathan S. FEBS J 278 4467-4485 (2011)
  14. Glycan-based high-affinity ligands for toxins and pathogen receptors. Kulkarni AA, Weiss AA, Iyer SS. Med Res Rev 30 327-393 (2010)
  15. Membrane-Binding Mechanism of Clostridium perfringens Alpha-Toxin. Oda M, Terao Y, Sakurai J, Nagahama M. Toxins (Basel) 7 5268-5275 (2015)
  16. Botulinum neurotoxin: where are we with detection technologies? Singh AK, Stanker LH, Sharma SK. Crit Rev Microbiol 39 43-56 (2013)
  17. What next for botulism vaccine development? Webb RP, Smith LA. Expert Rev Vaccines 12 481-492 (2013)
  18. Botulinum Toxin as a Pain Killer: Players and Actions in Antinociception. Kim DW, Lee SK, Ahnn J. Toxins (Basel) 7 2435-2453 (2015)
  19. Protein Toxins That Utilize Gangliosides as Host Receptors. Zuverink M, Barbieri JT. Prog Mol Biol Transl Sci 156 325-354 (2018)
  20. Unique ganglioside binding by botulinum neurotoxins C and D-SA. Kroken AR, Karalewitz AP, Fu Z, Baldwin MR, Kim JJ, Barbieri JT. FEBS J 278 4486-4496 (2011)
  21. Botulinum neurotoxins: new questions arising from structural biology. Kammerer RA, Benoit RM. Trends Biochem Sci 39 517-526 (2014)
  22. Variability of Botulinum Toxins: Challenges and Opportunities for the Future. Rasetti-Escargueil C, Lemichez E, Popoff MR. Toxins (Basel) 10 E374 (2018)

Articles citing this publication (60)